Atlas Trials

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Clinical trial NCT06483347 · RECRUITING

Trial details

NCT number
NCT06483347
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung CancerInoperable Disease
Start date
2024-04-04
Primary completion
2028-12-30
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.